摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Amino-2-methyl-2H-indazol | 97990-19-7

中文名称
——
中文别名
——
英文名称
3-Amino-2-methyl-2H-indazol
英文别名
3-Amino-2-methylindazole;2-Methyl-2H-indazol-3-amine;2-methylindazol-3-amine
3-Amino-2-methyl-2H-indazol化学式
CAS
97990-19-7
化学式
C8H9N3
mdl
MFCD19205547
分子量
147.18
InChiKey
TXPHCQAYEMUUOL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    164-165 °C(Solv: benzene (71-43-2))
  • 沸点:
    354.8±15.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    43.8
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
  • 危险性描述:
    H315,H319

SDS

SDS:156ca1c7b8794cfebcddaf56f2cfd5ed
查看

反应信息

  • 作为反应物:
    描述:
    3-Amino-2-methyl-2H-indazol对甲苯磺酸甲酯乙腈 为溶剂, 反应 48.0h, 以94%的产率得到2-Methyl-3-(methylamino)-1H-indazolium-4-methylbenzolsulfonat
    参考文献:
    名称:
    Quast, Helmut; Fuss, Andreas; Nahr, Uwe, Chemische Berichte, 1985, vol. 118, # 6, p. 2164 - 2185
    摘要:
    DOI:
  • 作为产物:
    描述:
    N-氨基-1H-苯并吡唑 在 lithium aluminium tetrahydride 、 氢溴酸 作用下, 以 乙醚 为溶剂, 反应 2.0h, 生成 3-Amino-2-methyl-2H-indazol
    参考文献:
    名称:
    Rearrangement of N-(alkylamino)azoles in acid media: a new entry to C-amino-N-substituted azoles
    摘要:
    A ring-opening/ring-closure mechanism for the thermal rearrangement of 1-(alkylamino)pyrazoles into 5-amino-1-alkylpyrazoles in acid medium has been established. 1-(Benzylamino)pyrazoles show a different reactivity, affording bis(5-amino-1-benzyl-4-pyrazolyl)phenylmethanes. The reaction was extended to 1-(alkylamino)indazoles but failed in the case of 1-(alkylamino)-1,2,4-triazoles.
    DOI:
    10.1021/jo00031a042
点击查看最新优质反应信息

文献信息

  • [EN] STING AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE STING ET LEURS UTILISATIONS
    申请人:NIMBUS TITAN INC
    公开号:WO2020132582A1
    公开(公告)日:2020-06-25
    The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.
    本发明提供了化合物、其组合物以及使用这些化合物调节STING并治疗STING介导的疾病的方法。
  • New pyrazole derivatives as CRAC channel modulators
    申请人:Almirall, S.A.
    公开号:EP2848615A1
    公开(公告)日:2015-03-18
    The present invention relates to compounds of formula (I) which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.
    本发明涉及一种具有式(I)的化合物,它们是CRAC通道活性的抑制剂。本发明还涉及含有这些化合物的药物组合物、它们的制备过程以及它们在治疗中的应用。
  • Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
    申请人:Mallams K. Alan
    公开号:US20070066621A1
    公开(公告)日:2007-03-22
    In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    在其多种形式中,本发明提供了一类新颖的吡唑并[1,5-a]吡啶,吡唑并[1,5-c]嘧啶和2H-吲唑化合物的4-氰基,4-氨基和4-氨基甲基衍生物,以及咪唑并[1,2-a]吡啶和咪唑并[1,5-a]吡嗪化合物的5-氰基,5-氨基和5-氨基甲基衍生物作为细胞周期依赖性激酶的抑制剂,制备此类化合物的方法,含有一种或多种此类化合物的药物组合物,制备包含一种或多种此类化合物的药物制剂的方法,以及使用此类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
  • NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS
    申请人:Mallams Alan K.
    公开号:US20100137326A1
    公开(公告)日:2010-06-03
    In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    在其多种实施方式中,本发明提供了一种新型的4-氰基、4-氨基和4-氨甲基吡唑并[1,5-a]吡啶、吡唑并[1,5-c]嘧啶和2H-吲哚化合物以及5-氰基、5-氨基和5-氨甲基咪唑并[1,2-a]吡啶和咪唑并[1,5-a]吡嗪化合物,作为细胞周期蛋白依赖性激酶的抑制剂,制备这种化合物的方法,含有一种或多种这种化合物的制药组合物,制备包含一种或多种这种化合物的制药配方的方法,以及使用这种化合物或制药组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
  • 10.1016/j.ejmech.2024.116620
    作者:La, Minh Thanh、Hoang, Van-Hai、Sahu, Raghaba、Nguyen, Cong-Truong、Nam, Gibeom、Park, Hyun-Ju、Park, Minsu、Kim, Yoon-Jae、Kim, Ji Young、Ann, Jihyae、Seo, Jae Hong、Lee, Jeewoo
    DOI:10.1016/j.ejmech.2024.116620
    日期:——
    A series of indazole analogs, derived from the B,C-ring-truncated scaffold of deguelin, were designed to function as C-terminal inhibitors of heat shock protein 90 (HSP90) and investigated as novel antitumor agents against HER2-positive breast cancer. Among the synthesized compounds, compound 12d exhibited substantial inhibitory effects in trastuzumab-sensitive (BT474) and trastuzumab-resistant (JIMT-1)
    一系列吲唑类似物来源于 deguelin 的 B,C 环截短支架,被设计为热休克蛋白 90 (HSP90) 的 C 末端抑制剂,并作为针对 HER2 阳性乳腺癌的新型抗肿瘤药物进行研究。在合成的化合物中,化合物 12d 对曲妥珠单抗敏感 (BT474) 和曲妥珠单抗耐药 (JIMT-1) 乳腺癌细胞表现出显著的抑制作用,IC50 值分别为 6.86 和 4.42 μM。值得注意的是,化合物 12d 在正常细胞中没有表现出细胞毒性。化合物 12d 在两种细胞类型中均显著下调主要 HSP90 客户蛋白的表达,将其细胞毒性归因于 HSP90 客户蛋白的不稳定和失活。使用 HSP90 同源二聚体同源模型的分子对接研究表明,抑制剂 12d 非常适合 C 端结构域,具有比 ATP 更高的静电互补评分。
查看更多